Severe Acute Respiratory Syndrome
48
0
1
31
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
11 trials with published results (23%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
8.3%
4 terminated out of 48 trials
88.6%
+2.1% vs benchmark
27%
13 trials in Phase 3/4
35%
11 of 31 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 31 completed trials
Clinical Trials (48)
Steroid Treatment for Severe Acute Respiratory Infection (STAR) Trial
Safety and Tolerability of COVID-19 Vaccine (ABNCoV2)
Intermediate IND Severe Illness COVID-19 CP
Study of the Pathogenesis of Olfactory Disorders in COVID-19
LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)
COVID-19 Health Professional Impact Study
Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19
Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure
Northeast COVID-19 and Pregnancy Study Group
Effect of Early Implementation of Prone Positioning
Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial
Prevalence of Antibodies Against SARS-CoV-2 Virus That Causes COVID-19 in Tübingen Children
A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
Methylprednisolone vs. Dexamethasone in COVID-19 Pneumonia (MEDEAS RCT)
COVID-19: A Study to Evaluate Safety, Reactogenicity and Immunogenicity of the SARS-CoV-2 mRNA Vaccine CVnCoV in Adults With Co-morbidities